Trim 25% of TMO at $608 immediately; retain 75% core residual with structural stop at $545
The Research Manager's Underweight rating is correct given empirical deterioration (FCF -13.4% YoY, OCF -9.8% YoY, gross margin -130bps, interest expense nearly doubled) at a 32.79x TTM P/E. However, the 9/1 Underweight reflection binds against full Sell: aggressive trims on defensive compounders with intact structure (golden cross, 0.85 beta, $6B+ FCF, recurring consumables base) harvest into rallies. The calibrated synthesis trims NOW at 25% (lighter than Research Manager's 30-50% or trader's 50%) to acknowledge deterioration without repeating the aggressive-trim mistake. Structural stop at $545 sits between 50 SMA ($563) and 200 SMA ($535), giving the thesis room to resolve while protecting against catastrophic breakdown.
| Position | Action |
|---|---|
| Current position at $608 | Trim 25% immediately |
| Price push toward $625-$650 with expanding volume | Trim additional portion if price reaches $635-$650 |
| Weekly close below $535 | Hard exit entire position |
Thermo Fisher Scientific is a high-quality defensive compounder with accelerating earnings growth, fortress-level cash generation, and a constructive technical setup offering a 4-5:1 risk/reward on any pullback to the $562–$570 zone.
| Indicator | Value | Signal |
|---|---|---|
| 50 SMA | 562.99 | bullish |
| 200 SMA | 534.77 | bullish |
| 10 EMA | 614.07 | neutral |
| RSI (14) | 56.57 | neutral |
| MACD | 16.04 | neutral |
| MACD Signal | 19.40 | neutral |
| MACD Histogram | -3.36 | bearish |
| Bollinger Middle (20 SMA) | 606.80 | neutral |
| Bollinger Upper Band | 643.46 | neutral |
| Bollinger Lower Band | 570.15 | neutral |
| ATR (14) | 16.67 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
↩ rebuts: “Margins are compressing concern”
EV: +5.7% (implied target $643+ from $608 entry vs $562–$570 stop loss zone) · concedes: Bear correctly identifies premium valuation (Forward P/E 22.14x, PEG 1.79) — but argues this is justified by quality and growth trajectory; PACB overhang is a real near-term sentiment headwind, even if the fundamental read-through is weak; Short-term momentum has indeed cooled (RSI dropped from 75 to 56, MACD mildly negative) — bull accepts this is a consolidation period; Net debt of $29.5B is elevated and worth monitoring, though manageable at 4.7x Net Debt/FCF
TMO is a quality compounder priced for a 48% EPS miracle that will not materialize; actual earnings grow at mid-single digits, cash flow is deteriorating, leverage is rising, and the multiple has room to compress in a higher-for-longer rate environment—making this a Hold/Sell, not a buy.
· concedes: TMO's diversified buffer provides some protection against category-level slowdown; Light volume pullback could indicate sellers are exhausted, not just buyers absent; No impairments have occurred yet despite high goodwill; Defensive characteristics provide some downside cushion in downturns; EPS trajectory, while below 48%, does show positive compounding
→ vs conservative: Long-term trend (50 SMA above 200 SMA, price above both) is irrelevant at 32x P/E with collapsing FCF; chart analysis is momentum worship, not fundamental analysis
→ vs conservative: Waiting to add at 563 on a name with doubling leverage costs, contracting FCF, and 22-32x forward earnings makes no sense when structural earnings power is deteriorating
→ vs conservative: Defensive characteristics protect revenue but not multiples when discount rates rise and earnings streams narrow on a leveraged balance sheet with $29.5B net debt
→ vs conservative: Analyst bullishness is a coincident indicator, not forward-looking; outperformance over trailing year means product cycle is already priced in
→ vs neutral: HOLD means full downside exposure at 32x earnings with negative FCF/OCF growth and compressed margins; waiting for 562 'add zone' is passive when 570 breaks on volume
→ vs neutral: Framing RSI cooling from 75 to 56 as 'constructive' ignores momentum rolling over, MACD below signal, and price below 10 EMA; bearish momentum signals argue for trim, not holding
| neutral |
| VWMA | 614.04 | neutral |
| Close | 608.54 | neutral |
| RSI Peak (2026-08-26) | 75.34 | bearish |
Support: 570.15 · 562.99 · 534.77 | Resistance: 614.07 · 643.46
TMO technical analysis as of 2026-09-02 shows a mature uptrend in a healthy cool-off phase. Long-term trend remains bullish with price (+13.8% above 200 SMA, +8.1% above 50 SMA), but short-term momentum has shifted bearish with MACD negative histogram (-3.36) and price rejected below the 10 EMA. RSI has corrected from overbought extremes (75.34 to 56.57), relieving overbought pressure without breaking the uptrend structure. Current price (608.54) is sitting on the Bollinger midline with resistance at 614 (10 EMA/VWMA) and 643.46 (upper band), while support lies at 570.15 (lower band), 562.99 (50 SMA), and 534.77 (200 SMA). Volume analysis shows the pullback occurred on light volume, suggesting constructive consolidation rather than distribution. The overall recommendation is HOLD with tactical bias toward accumulation on weakness toward 562-570, or a bullish trigger on close above 614 on rising volume targeting 643+.
Market Cap
$225.0B
P/E Ratio (TTM)
32.79
Forward P/E
22.14
PEG Ratio
1.79
Price/Book
4.27
EPS (TTM)
$18.56
Forward EPS
$27.49
Dividend Yield
0.31%
52-Week High
$647.00
52-Week Low
$435.27
50-Day MA
$563.26
200-Day MA
$535.50
Beta
0.847
Total Revenue (FY2025)
44,557
Gross Profit (FY2025)
18,239
Gross Margin (FY2025)
40.9%
Operating Income (FY2025)
8,110
Operating Margin (FY2025)
18.2%
EBITDA (FY2025)
11,507
EBITDA Margin (TTM)
25.3%
Net Income (FY2025)
6,704
Diluted EPS (FY2025)
$17.74
R&D (FY2025)
1,397
SG&A (FY2025)
8,732
Tax Rate (FY2025)
7.5%
Total Assets (FY2025)
110,343
Total Equity (FY2025)
53,407
Total Debt (FY2025)
39,385
Net Debt (FY2025)
29,533
Cash & Equivalents (FY2025)
9,852
Goodwill + Intangibles (FY2025)
65,200
Working Capital (FY2025)
13,518
Current Ratio (FY2025)
1.55
Debt/Equity (FY2025)
0.74
Operating Cash Flow (FY2025)
7,818
CapEx (FY2025)
-1,525
Free Cash Flow (FY2025)
6,293
Free Cash Flow (TTM)
$6.24B
Acquisitions (FY2025)
-4,037
Dividends Paid (FY2025)
-636
Buybacks (FY2025)
-3,000
Profit Margin (TTM)
15.04%
ROE (TTM)
13.52%
ROA (TTM)
5.13%
Shares Outstanding (Diluted, TTM)
~378 million
Strengths
Concerns
Thermo Fisher Scientific is a mega-cap life sciences leader with FY2025 revenue of $44.56B and net income of $6.7B, demonstrating recovery from post-COVID normalization. The valuation setup appears attractive with a forward P/E of 22.14 against ~48% expected EPS growth, while best-in-class EBITDA margins of 25.3% and $6.24B in annual free cash flow support the company's investment-grade profile and disciplined capital return program of $3-4B in annual buybacks. Key risks to monitor include gross margin compression, elevated leverage with $29.5B net debt, $49.4B+ goodwill impairment risk, and geopolitical headwinds from China exposure.
Macro: Fed policy: Polymarket prices 89% probability of no rate cuts in 2026 (up 1.6pp on the week), effectively pricing out any easing cycle. Recession risk: Only 8% probability of US recession by year-end 2026 (down 1.0pp), with Japan and UK tails similarly benign, supporting durable demand from pharma R&D, hospital labs, and academic end-markets. Global tone: Risk-on neutral (Wall St higher, yields easing, gold flat) — constructive for healthcare defensives not dependent on cyclical capex. Rate implications: Higher-for-longer creates headwind for long-duration growth multiples given TMO's premium valuation; USD support may create ~40% non-USD revenue translation drag.